Twist Bioscience reorganized its revenue reporting into a single 'DNA synthesis and protein solutions' segment as AI‑driven drug discovery increased cross‑product demand. CEO Emily Leproust cited orders from customers using AI workflows as a material revenue driver and said larger integrated purchases—DNA, genes, proteins, characterization—are blurring historical business lines. Twist also reported fiscal Q4 growth and highlighted that AI‑based discovery contributed roughly $25 million of revenue growth in the prior year, including its largest single purchase order to date. The company will not structurally reorganize operations but will align reporting to reflect convergent customer workflows. The move signals commercial tailwinds for synthetic‑biology vendors as pharma and tech firms embed DNA‑to‑protein supply chains into AI discovery pipelines.